Cover Image
市場調查報告書

HIV疫苗市場機會與臨床實驗平台分析

HIV Vaccine Market Opportunity & Clinical Pipeline Analysis

出版商 KuicK Research 商品編碼 302593
出版日期 內容資訊 英文 330 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
HIV疫苗市場機會與臨床實驗平台分析 HIV Vaccine Market Opportunity & Clinical Pipeline Analysis
出版日期: 2014年03月01日 內容資訊: 英文 330 Pages
簡介

30年前確定HIV為AIDS的原因以來,HIV病毒成為了全世界國家所面臨的公共衛生最大課題之一。根據UNAIDS,AIDS造成的死亡2012年約近150萬人。又有230萬人感染HIV,現在有3,530萬人有HIV。

本報告提供HIV疫苗及機制的簡介、全球HIV發病率趨勢、研究開發、法律規範趨勢、臨床實驗趨勢等,以及參與企業的競爭環境彙整,為您概述為以下內容。

第1章 HIV疫苗及機制的簡介

  • 簡介
  • HIV疫苗的機制

第2章 HIV疫苗:預防和治療

  • 預防
  • 治療和抗逆轉濾病毒治療的點閱存取

第3章 為何需要HIV疫苗

第4章 全球HIV病毒市場預測

  • HIV發病率方案
  • 市場概要
  • 臨床實驗分析

第5章 HIV疫苗相關研究開發費用方案

第6章 市場趨勢

  • 推動市場的要素
  • 應解決的課題
  • 未來的成長的機會

第7章 HIV疫苗開發相關FDA的法規結構

  • 兒童用的預防性HIV疫苗的開發
  • HIV耐藥性資料繳交相關指導
  • 抗逆轉濾病毒藥物開發的HIV耐藥性檢驗

第8章 相,各國開發平台

第9章 相,各國中斷、中止的HIV疫苗臨床實驗簡介

第10章 競爭環境

  • Antigen Express
  • Bionor Pharma
  • FIT Biotech
  • GeoVax
  • GenVec
  • Glaxo Smithkline
  • Immune Response BioPharma
  • Inovio Pharmaceuticals
  • Novartis
  • Sanofi Pasteur

圖表

目錄

Ever since HIV was identified as the cause for AIDS 30 years ago, the HIV virus has become one of the greatest challenges of public health facing all countries of the world. According to UNAIDS, death due to AIDS was estimated to close to 1.6 million in 2012. There were 2.3 million new HIV infections, and about 35.3 million people currently living with HIV. Given the pace at which the HIV virus is spreading, it is most likely that AIDS would take more lives than any other infectious disease in the future years to come. Inspite of well-expanded programs of prevention and treatment which are currently enabling the stakeholders to address the illness and death associated with HIV and AIDS, the HIV vaccines is considered to be the best solution to end this disease successfully.

HIV/AIDS has become of the leading infectious disease which is taking a huge death toll across the globe, even surpassing TB and malaria. Irrespective of whether the country is developed or developing, the disease is increasingly becoming prevalent, though with serious impact in the developing countries. It has been observed that almost nine out of every ten HIV infections are being diagnosed in the developing countries, and two-thirds are in Sub-Saharan Africa. India currently has close to 4 million infected people, which is the largest number of infected persons of any country in the world. Despite of the combating efforts, the Asian and other developing regions are increasingly feeling the heat as HIV continues to spread at a significant rate.

In recent years there have been significant breakthroughs achieved in terms of prevention and treatment of HIV/AIDS. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and an efficient vaccine, with the help of adequate funding. Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future.

It is expected that in the next 5-8 years, the pharmaceutical companies would focus more on the development of a successful efficient vaccine to control the spread of this disease. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions. There needs to be complete scrutiny of every single technological area of HIV prevention R&D so as to reflect the best methods of channelizing the funds which are limited in nature. The funds need to be specifically directed towards only those products and approaches which have a high probability of succeeding, instead of those which are less promising.

"HIV Vaccine Market Opportunity & Clinical Pipeline Analysis" Report Highlights:

  • Introduction to HIV Vaccine & Mechanism
  • Global HIV Incidence Scenario
  • R&D Funding Scenario for HIV Vaccine
  • FDA Regulatory Framework
  • HIV Vaccine Clinical Trial by Phase & Country
  • HIV Vaccines in Development Phase: More Than 100
  • Most HIV Vaccines in Preclinical Phase: More Than 50
  • Discontinued & Suspended HIV Vaccines Profiles

Table of Contents

1. Introduction to HIV Vaccine & Mechanism

  • 1.1. Introduction
  • 1.2. The Mechanics of HIV Vaccines

2. HIV Vaccine: Prevention & Cure

  • 2.1. Prevention
  • 2.2. Cure & Access to Antiretroviral Therapy

3. Why Need For HIV Vaccines?

4. Global HIV Vaccine Market Outlook

  • 4.1. HIV Incidence Scenario
  • 4.2. Market Overview
  • 4.3. Clinical Trial Analysis

5. Research & Development Funding Scenario for HIV Vaccine

6. HIV Vaccine Market Dynamics

  • 6.1. Favorable Market Drivers
  • 6.2. Challenges to be Resolved
  • 6.3. Future Growth Opportunity

7. FDA Regulatory Framework for Development of HIV Vaccine

  • 7.1. Development of Preventive HIV Vaccines for Use in Paediatric Populations
  • 7.2. Guidance for Submitting HIV Resistance Data
  • 7.3. HIV Resistance Testing in Antiretroviral Drug Development

8. HIV Vaccine Clinical Trial by Phase & Country

  • 8.1. Research
  • 8.2. Preclinical
  • 8.3. Clinical
  • 8.4. Phase I
  • 8.5. Phase I/II
  • 8.6. Phase II
  • 8.7. Phase III

9. Discontinued & Suspended HIV Vaccine Clinical Trial by Phase & Country

  • 9.1. No Development Reported
  • 9.2. Discontinued
  • 9.3. Suspended

10. Competitive Landscape

  • 10.1. Antigen Express
  • 10.2. Bionor Pharma
  • 10.3. FIT Biotech
  • 10.4. GeoVax
  • 10.5. GenVec
  • 10.6. Glaxo Smithkline
  • 10.7. Immune Response BioPharma
  • 10.8. Inovio Pharmaceuticals
  • 10.9. Novartis
  • 10.10. Sanofi Pasteur

List of Figures

  • Figure 1-1: Vaccine Research Process
  • Figure 4-1: People Living With HIV Infection (Million), 2009-2014
  • Figure 4-2: New Incidence of HIV Infection (Million), 2009-2012
  • Figure 4-3: People Living With HIV Infection by Region (%), 2012
  • Figure 4-4: People Accessing Treatment for HIV Infection (Million), 2009-2012
  • Figure 4-5: Global HIV/AIDS Therapeutics Market (US$ Billion), 2012-2018
  • Figure 4-6: HIV Vaccines in Clinical Trial by Phase (%), 2014
  • Figure 4-7: Number of HIV Vaccines in Clinical Trial by Phase, 2014
  • Figure 4-8: Suspended & Discontinued HIV Vaccines in Clinical Trial (%), 2014
  • Figure 4-9: Number of Suspended & Discontinued HIV Vaccines in Clinical Trial, 2014
  • Figure 4-10: Discontinued HIV Vaccines in Clinical Trial by Phase (%), 2014
  • Figure 4-11: Number of Discontinued HIV Vaccines in Clinical Trial by Phase, 2014
  • Figure 4-12: HIV Vaccines in Clinical Trial by Phase Where No Development Reported (%), 2014
  • Figure 4-13: Number of HIV Vaccines in Clinical Trial by Phase Where No Development Reported, 2014
  • Figure 5-1: Global HIV Vaccines R&D Funding (US$ Million), 2005-2012
  • Figure 5-2: Global HIV Vaccines R&D Funding Breakup (%), 2012
  • Figure 5-3: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%),2012

List of Tables

  • Table 5-1: HIV Vaccines Funding by Sector (US$ Million), 2006-2012
  • Table 6-1: HIV Vaccine Impact Analysis on Incidence & Deaths
Back to Top